glp-1 cardiovascular outcome trials Cardiovascular, mortality, and kidney outcomes with receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised Impact of GLP-1 receptor agonists
Description
Am Heart Hournal Plus Cardiol Res Pract

Li H, Chen X, Guan L, Qi Q, Shu G, Jiang Q, et al

The short answer is that no clinically significant interaction has been identified in major drug interaction databases or FDA labeling

Diabetes Care 44 , 765773 (2021)

Nature 543 , 424427 (2017)

coli did not affect the host
